

**Editor**

Tore K Kvien

Associate Editors

Francis Berenbaum
Hans Bijlsma
David Pisetsky
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 9.111

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2014 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Techset and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.
Register using this QR code.

Contents

Volume 73 Issue 1 | ARD January 2014

Editorial

- 1** Classification criteria for Sjögren's syndrome: nothing ever stands still!
S J Bowman, R I Fox

Viewpoint

- 3** Proposal for a new nomenclature of disease-modifying antirheumatic drugs
J S Smolen, D van der Heijde, K P Machold, D Aletaha, R Landewé

Recommendations

- 6** Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
J S Smolen, J Braun, M Dougados, P Emery, O FitzGerald, P Helliwell, A Kavanaugh, T K Kvien, R Landewé, T Luger, P Mease, I Olivieri, J Reveille, C Ritchlin, M Rudwaleit, M Schoels, J Sieper, M de Wit, X Baraliakos, N Betteridge, R Burgos-Vargas, E Collantes-Estevez, A Deodhar, D Elewaut, L Gossec, M Jongkees, M Maccarone, K Redlich, F van den Bosch, J Cheng-Chung Wei, K Winthrop, D van der Heijde
- 17** International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies
N Agmon-Levin, J Damoiseaux, C Kallenberg, U Sack, T Witte, M Herold, X Bossuyt, L Musset, R Cervera, A Plaza-Lopez, C Dias, M José Sousa, A Radice, C Eriksson, O Hulthgren, M Viander, M Khamashta, S Regenass, L E C Andrade, A Witte, A Tincani, J Rönnelid, D B Bloch, M J Fritzler, E K L Chan, I Garcia-De La Torre, K N Konstantinov, R Lahita, M Wilson, O Vainio, N Fabien, R A Sinico, P Meroni, Y Shoenfeld

Review

- 24** Hepatitis C virus-induced vasculitis: therapeutic options
P Cacoub, B Terrier, D Saadoun

Clinical and epidemiological research

- 31** Comparison of the American-European Consensus Group Sjögren's syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort
A Rasmussen, J A Ice, H Li, K Grundahl, J A Kelly, L Radfar, D U Stone, K S Hefner, J-M Anaya, M Rohrer, R Gopalakrishnan, G D Houston, D M Lewis, J Chodosh, J B Harley, P Hughes, J S Maier-Moore, C G Montgomery, N L Rhodus, A D Farris, B M Segal, R Jonsson, C J Lessard, R H Scofield, K L M Sivils
- 39** Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
R Landewé, J Braun, A Deodhar, M Dougados, W P Maksymowych, P J Mease, J D Reveille, M Rudwaleit, D van der Heijde, C Stach, B Hoepken, A Fichtner, G Coteur, M de Longueville, J Sieper
- 48** Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
P J Mease, R Fleischmann, A A Deodhar, J Wollenhaupt, M Khraishi, D Kieler, F Woltering, C Stach, B Hoepken, T Arledge, D van der Heijde
- 56** Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial
N P Quillinan, D McIntosh, J Vernes, S Haq, C P Denton
- 62** Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)
M Dougados, M Soubrier, A Antunez, P Balint, A Balsa, M H Buch, G Casado, J Deter, B El-zorany, P Emery, N Hajjaj-Hassouni, M Harigai, S-F Luo, R Kurucz, G Maciel, E M Mola, C M Montecucco, I McInnes, H Radner, J S Smolen, Y-W Song, H E Vonkeman, K Winthrop, J Kay
- 69** A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
G R Burmester, A Rubbert-Roth, A Cantagrel, S Hall, P Leszczynski, D Feldman, M J Rangaraj, G Roane, C Ludvico, P Lu, L Rowell, M Bao, E F Mysler
- 75** Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naïve, rheumatoid arthritis (the IDEA study)
J L Nam, E Villeneuve, E M A Hensor, P G Conaghan, H I Keen, M H Buch, A K Gough, M J Green, P S Helliwell, A M Keenan, A W Morgan, M Quinn, R Reece, D M van der Heijde, R J Wakefield, P Emery
- 86** Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
M Schiff, M E Weinblatt, R Valente, D van der Heijde, G Citera, A Elegbe, M Maldonado, R Fleischmann
- 95** Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials
J Sieper, B Porter-Brown, L Thompson, O Harari, M Dougados

MORE CONTENTS ►

EDITOR'S
CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals Open Access scheme.
See <http://ard.bmj.com/site/about/guidelines.xhtml#open>



COPE

COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

www.publicationethics.org.uk



equator
network



recycle
When you have finished
with this please recycle it

- 101** Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1
J Sieper, J Lenaerts, J Wollenhaupt, M Rudwaleit, V I Mazurov, L Myasoutova, S Park, Y Song, R Yao, D Chitkara, N Vastesaeger, on Behalf of All INFAST Investigators
- 108** Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2
J Sieper, J Lenaerts, J Wollenhaupt, M Rudwaleit, V I Mazurov, L Myasoutova, S Park, Y Song, R Yao, D Chitkara, N Vastesaeger, on Behalf of All INFAST Investigators
- 114** Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review
H Radner, T Neogi, J S Smolen, D Aletaha
- 124** Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study
I B McInnes, H-Y Kim, S-H Lee, D Mandel, Y-W Song, C A Connell, Z Luo, M J Brosnan, A Zuckerman, S H Zwilllich, J D Bradley
- 132** The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study
K M Fagerli, E Lie, D van der Heijde, M S Heiberg, Å S Lexberg, E Rødevand, S Kalstad, K Mikkelsen, T K Kvien
- 138** Lymphoma risk in systemic lupus: effects of disease activity versus treatment
S Bernatsky, R Ramsey-Goldman, L Joseph, J-F Boivin, K H Costenbader, M B Urowitz, D D Gladman, P R Fortin, O Nived, M A Petri, S Jacobsen, S Manzi, E M Ginzler, D Isenberg, A Rahman, C Gordon, G Ruiz-Irastorza, E Yelin, S-C Bae, D J Wallace, C A Peschken, M A Dooley, S M Edworthy, C Aranow, D L Kamen, J Romero-Diaz, A Askanase, T Witte, S G Barr, L A Criswell, G K Sturfelt, I Blanco, C H Feldman, L Dreyer, N M Patel, Y St Pierre, A E Clarke
- 143** Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis
S L Mackie, E M A Hensor, A W Morgan, C T Pease
- 149** Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study
A Ogdie, K Haynes, A B Troxel, T J Love, S Hennessy, H Choi, J M Gelfand
- 154** Annual direct medical cost of active systemic lupus erythematosus in five European countries
A Doria, Z Amoura, R Cervera, M A Khamashta, M Schneider, J Richter, F Guillemain, G Kobelt, F Maurel, A Garofano, A Perna, M Murray, C Schmitt, I Boucot
- 161** Effects of golimumab, an anti-tumour necrosis factor- α human monoclonal antibody, on lipids and markers of inflammation
B W Kirkham, M C Wasko, E C Hsia, R M Fleischmann, M C Genovese, E L Matteson, H Liu, M U Rahman
- 170** *MicroRNA-146a* and *Ets-1* gene polymorphisms in ocular Behçet's disease and Vogt–Koyanagi–Harada syndrome
Q Zhou, S Hou, L Liang, X Li, X Tan, L Wei, B Lei, A Kijlstra, P Yang
- 177** Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout
F Perez-Ruiz, L Martínez-Indart, L Carmona, A M Herrero-Beites, J I Pijoan, E Krishnan
- 183** Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
D J Wallace, K Kalunian, M A Petri, V Strand, F A Houssiau, M Pike, B Kilgallen, S Bongardt, A Barry, L Kelley, C Gordon
- 191** Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis
J Avouac, D Huscher, D E Furst, C F Opitz, O Distler, Y Allaire, for the EPOSS group
- 198** Inequities in access to biologic and synthetic DMARDs across 46 European countries
P Putrik, S Ramiro, T K Kvien, T Sokka, M Pavlova, T Uhlig, A Boonen, Working Group 'Equity in access to treatment of rheumatoid arthritis in Europe'
- 207** The characterisation and determinants of quality of life in ANCA associated vasculitis
N Basu, A McClean, L Harper, E N Amft, N Dhaun, R A Luqmani, M A Little, D R W Jayne, O Flossmann, J McLaren, V Kumar, L P Erwig, D M Reid, G T Jones, G J Macfarlane
- 212** International comparisons of the consultation prevalence of musculoskeletal conditions using population-based healthcare data from England and Sweden
K P Jordan, A Jöud, C Berggren, P Croft, J J Edwards, G Peat, I F Petersson, A Turkiewicz, R Wilkie, M Englund
- 219** Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results from the European Prospective Investigation of Cancer-Norfolk and the Norfolk Arthritis Register—the EPIC-2-NOAR Study)
M Lahiiri, R N Luben, C Morgan, D K Bunn, T Marshall, M Lunt, S M M Verstappen, D P M Symmons, K-T Khaw, N Wareham, I N Bruce
- 227** Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients
R Aggarwal, E Cassidy, N Fertig, D C Koontz, M Lucas, D P Ascherman, C V Oddis
- 233** Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol
D van der Heijde, R Fleischmann, J Wollenhaupt, A Deodhar, D Kielar, F Woltering, C Stach, B Hoepken, T Arledge, P J Mease
- 238** Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis
M M Schoels, J Braun, M Dougados, P Emery, O Fitzgerald, A Kavanaugh, T K Kvien, R Landewé, T Luger, P Mease, I Olivier, J Reveille, C Richlin, M Rudwaleit, J Sieper, J S Smolen, M de Wit, D van der Heijde

- 243** Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial
H Haibel, C Fendler, J Listing, J Callhoff, J Braun, J Sieper
- 247** Correlations between nailfold microangiopathy severity, finger dermal thickness and fingertip blood perfusion in systemic sclerosis patients
A Sulli, B Ruaro, E Alessandri, C Pizzorni, M A Cimmino, G Zampogna, M Gallo, M Cutolo
- 252** The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA
J Závada, M Lunt, R Davies, A SL Low, L K Mercer, J B Galloway, K D Watson, D P Symmons, K L Hyrich, on behalf of the British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium

Basic and translational research

- 256** A phase 1b clinical trial evaluating sifalimumab, an anti-IFN- α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
B W Higgs, W Zhu, C Morehouse, W I White, P Brohawn, X Guo, M Rebelatto, C Le, A Amato, D Fiorentino, S A Greenberg, J Drappa, L Richman, W Greth, B Jallal, Y Yao
- 263** Heightened immune response to autocitrullinated *Porphyromonas gingivalis* peptidylarginine deiminase: a potential mechanism for breaching immunologic tolerance in rheumatoid arthritis
A-M Quirke, E B Lugli, N Wegner, B C Hamilton, P Charles, M Chowdhury, A J Ytterberg, R A Zubarev, J Potempa, S Culshaw, Y Guo, B A Fisher, G Thiele, T R Mikuls, P J W Venables
- 270** Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis
P Suwannalai, K Britsenmer, R Knevel, H U Scherer, E W N Levarht, A H van der Helm-van Mil, D van Schaardenburg, T W J Huizinga, R E M Toes, L A Trouw
- 277** Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response
P Enghard, C Rieder, K Kopetschke, J R Klocke, R Undeutsch, R Biesen, D Dragun, M Gollasch, U Schneider, K Aupperle, J Y Humrich, F Hiepe, M Backhaus, A H Radbruch, G R Burmester, G Riemekasten
- 284** Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone
A J Preston, C M Keenan, H Sutherland, P J Wilson, B Wlodarski, A M Taylor, D P Williams, L R Ranganath, J A Gallagher, J C Jarvis
- 290** Identification of a new exon 2-skipped TNFR1 transcript: regulation by three functional polymorphisms of the TNFR-associated periodic syndrome (TRAPS) gene
C Rittore, E Sanchez, S Soler, M Barat-Houari, M Albers, L Obici, M F McDermott, I Toubiou, S Grandemange

- 298** Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis
B Orosa, S García, P Martínez, A González, J J Gómez-Reino, C Conde
- 306** IL-7 receptor α expressing B cells act proinflammatory in collagen-induced arthritis and are inhibited by sympathetic neurotransmitters
G Pongratz, J M Anthofer, M Melzer, S Anders, S Grässel, R H Straub

Letters

- 313** Population-specific effects of *SLC17A1* genotype on serum urate concentrations and renal excretion of uric acid during a fructose load
N Dalbeth, M E House, G D Gamble, A Home, L Purvis, A Stewart, M Merriman, M Cadzow, A Phipps-Green, T R Merriman
- 315** Contribution of the COMT Val158Met variant to symptomatic knee osteoarthritis
T Neogi, A Soni, S A Doherty, L L Laslett, R A Maciewicz, D J Hart, W Zhang, K R Muir, M Wheeler, C Cooper, T D Spector, F Cicuttini, G Jones, M Nevitt, Y Liu, N K Arden, M Doherty, A M Valdes
- 317** Association of medication beliefs and selfefficacy with adherence in urban Hispanic and African-American rheumatoid arthritis patients
T M Spruill, G Ogedegbe, L R Harrold, J Potter, J U Scher, P B Rosenthal, J D Greenberg
- 318** Disease assessment in psoriatic spectrum: a modular approach for use in routine clinical practice
J Wajed, P Helliwell, E Korendowych, K Gadsby, S Oliver, L Parrish, B Kirkham

Miscellaneous

- 320** Correction

Electronic pages

- e1** Is TNF- α really involved in giant cell arteritis pathogenesis?
M Samson, S Audia, N Janikashvili, B Bonnotte
- e2** Impact of gender on outcomes in ankylosing spondylitis
E Feldtkeller, G Lind-Albrecht
- e3** Response to: 'Impact of gender on outcomes in ankylosing spondylitis' by Feldtkeller *et al*
I van der Horst-Bruinsma, D Zuck, A Szumski, A S Koenig
- e4** Biologic discontinuation studies: a systematic review of methods; comment on the article by Yoshida *et al*
A van der Maas, N van Herwaarden, A A den Broeder
- e5** Response to: 'Biologic discontinuation studies: a systematic review of methods' by van der Maas *et al*
K Yoshida, Y-K Sung, A Kavanaugh, S-C Bae, M E Weinblatt, M Kishimoto, K Matsui, S Tohma, D H Solomon